Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

REGENXBIO Faces Clinical Hold on RGX-121 but Duchenne BLA Advances

31 August 2026 · By · Wire by Fusion42

Published

31 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at streetwisereports.com →

◆ Verified

Fusion42 · 1 September 2026 · Fusion42 review

REGENXBIO's RGX-121 gene therapy for Hunter Syndrome faces an FDA clinical hold due to asymptomatic spinal MRI findings, while the Duchenne muscular dystrophy program remains on track for a Q3 2026 Biologics License Application (BLA) submission.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 24 Aug 2026 and 31 Aug 2026.

◆ ◆ The Wire takeaway

You must separate your development risks between gene therapy indications after RGX-121’s FDA hold. Duchenne-focused founders can push regulatory filings aggressively while Hunter Syndrome candidates face setbacks.

◆ Coverage

3 sources · first reported 24 Aug 2026 · latest 31 Aug 2026

◆ Related on Wire

◆ Topics

Biotechclinical-holdgene-therapyhunter-syndromeduchenne-muscular-dystrophyfdablaq-submission